Drug news
CHMP gives negative recommendation to Nerventra for Multiple Sclerosis-Teva
On 23 January 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Nerventra (laquinimod) from Teva, intended for the treatment of Multiple Sclerosis. The European Medicines Agency said it was concerned about elevated risk of cancers as well as a possible risk to unborn babies from the use of laquinimod,so Bloomberg reported.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.